No Data
Kangfeng Bio-B (06922.HK) plans to hold a Board of Directors meeting on March 31 to approve the annual performance.
Glory Holdings announced on March 19 that Kangfeng Bio-B (06922.HK) has scheduled a Board of Directors meeting on March 31, 2025 (Monday) to review and approve the group's annual performance for the year ended December 31, 2024, and its release, as well as to review the proposal for the distribution of a final dividend (if any).
Kangfeng Biotechnology-B (06922.HK): The malignant stenosis cryoablation system has obtained approval from the National Medical Products Administration.
Gelonghui, March 6th丨Kangfeng Biological-B (06922.HK) announced that on March 6, 2025, the group’s malignant stenosis cryoablation system, which is one of the group’s respiratory intervention products, consisting of cryotherapy equipment and airway cryoablation catheters, has obtained the approval from the National Medical Products Administration. The malignant stenosis cryoablation system is an independently developed cryoablation system used for ablating malignant airway tumor tissues and reducing the frequency of airway restenosis. During the surgical procedure, the malignant stenosis cryoablation system utilizes the ultra-low temperature generated by the cryoablation system to ablate tumor cells in the tracheal lumen and wall, and then proceed with reheating.
Express News | Cryofocus Medtech Shanghai - Nmpa Approval for Malignant Stenosis Cryoablation System
Private Companies Invested in Cryofocus Medtech (Shanghai) Co., Ltd. (HKG:6922) Copped the Brunt of Last Week's HK$466m Market Cap Decline
Kangfeng Biological - B [06922] is currently reported at 6.64 Hong Kong dollars, with a decline of 13.20%.
As of 15:07, Kangfeng Biotech - B [06922] is priced at 6.64 HKD, down 1.01 HKD or 13.20% from yesterday's closing price of 7.65 HKD, with a transaction value of 0.0804 million HKD. Today's highest price is 7.69 HKD, and the lowest price is 6.97 HKD. Based on yesterday's closing price, the 10-day average price is 7.88 HKD, the 50-day average price is 7.26 HKD, the current PE is -17.02 times, and the 14-day strength index is 30.53.
Cryofocus Medtech's Subsidiary to Collaborate on Research, Development of Cryoballoon Ablation for Lung Cancer
